Latest
By Staff Report / Tuesday, December 17th, 2013 / Central Coast Health Watch, Technology, Top Stories / Comments Off on Amgen spinout Atara raises $38.5 million
Atara Biotherapeutics, a Thousand Oaks firm that emerged last year with major Silicon Valley backers and licenses to develop six Amgen assets, has raised $38.5 million to pursue treatments for dialysis complications and ovarian cancer.
Read More →
Latest
By Staff Report / Thursday, November 7th, 2013 / East Ventura County, Technology, Top Stories / Comments Off on ImmunGene raises $9M
Thousand Oaks-based ImmunGene, a cancer treatment firm led by a former Amgen scientist, has raised $9 million from Ally Bridge Group, an investment group with ties to Hong Kong.
ImmunGene’s so-called antibody-cytokine fusion technology could help improve the cancer-cell targeting in therapies. President and CEO Sanjay D. Khare was formerly the scientific director at Amgen, the biotech giant. Prior to the funding, ImmunGene had received several hundred thousand dollars in federal research grants.
Read More →
Latest
By Stephen Nellis / Friday, October 11th, 2013 / Technology, Top Stories / Comments Off on Stellar’s $12M raise sets stage for drug rollout
Port Hueneme-based Stellar Biotechnologies has closed a $12 million round of financing and acquired a license for what could one day be its first drug. Stellar gained notoriety in the research world by snatching up a facility inside the Port of Hueneme gates during a round of base closings in the late 1990s. It used Read More →
Read More →
Latest
By Stephen Nellis / Friday, August 30th, 2013 / Banking & Finance, Technology, Top Stories / Comments Off on Onyx buy sets dealmaking era for Amgen
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Latest
By Henry Dubroff / Friday, August 30th, 2013 / Columns, Opinion / Comments Off on The top five financial truths in blockbuster Amgen-Onyx deal
For sheer size and scale, Amgen’s $10.4 billion purchase of South San Francisco-based cancer drug maker Onyx Pharmaceuticals dwarfs any recent deal in the Tri-Counties. For size, let’s remember that Dole Food Co. is selling its entire self for about $1.3 billion and that Santa Barbara Bank & Trust parent Pacific Capital Bancorp, previously the Read More →
Read More →
Latest
By Stephen Nellis / Friday, August 2nd, 2013 / Features, Technology / Comments Off on Breeding new biotech firms: Incubator in Thousand Oaks fosters startups
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
